ProShare Advisors LLC Sells 17,708 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

ProShare Advisors LLC lessened its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 15.5% during the second quarter, HoldingsChannel.com reports. The fund owned 96,203 shares of the medical instruments supplier’s stock after selling 17,708 shares during the period. ProShare Advisors LLC’s holdings in LeMaitre Vascular were worth $7,916,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. YHB Investment Advisors Inc. purchased a new position in LeMaitre Vascular in the 1st quarter worth approximately $36,000. GAMMA Investing LLC grew its stake in LeMaitre Vascular by 57.0% in the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after buying an additional 199 shares in the last quarter. West Oak Capital LLC purchased a new position in LeMaitre Vascular in the 2nd quarter worth approximately $58,000. nVerses Capital LLC grew its stake in LeMaitre Vascular by 33.3% in the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after buying an additional 200 shares in the last quarter. Finally, Van ECK Associates Corp purchased a new position in LeMaitre Vascular in the 2nd quarter worth approximately $75,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on LMAT. Roth Capital raised shares of LeMaitre Vascular to a “strong-buy” rating in a research note on Friday, May 31st. Lake Street Capital initiated coverage on shares of LeMaitre Vascular in a research note on Friday, August 2nd. They issued a “buy” rating and a $105.00 price objective for the company. JMP Securities increased their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. Roth Mkm reissued a “buy” rating and set a $100.00 price target on shares of LeMaitre Vascular in a research report on Friday, May 31st. Finally, Barrington Research reissued an “outperform” rating and set a $92.00 price target on shares of LeMaitre Vascular in a research report on Friday, September 20th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, LeMaitre Vascular has a consensus rating of “Moderate Buy” and a consensus target price of $94.40.

LeMaitre Vascular Trading Down 0.3 %

Shares of NASDAQ LMAT opened at $91.13 on Wednesday. LeMaitre Vascular, Inc. has a 12 month low of $44.27 and a 12 month high of $92.90. The firm has a market capitalization of $2.05 billion, a PE ratio of 60.35, a price-to-earnings-growth ratio of 2.28 and a beta of 0.88. The firm has a fifty day simple moving average of $87.02 and a two-hundred day simple moving average of $78.47.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 EPS for the quarter, topping the consensus estimate of $0.47 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The business had revenue of $55.85 million during the quarter, compared to analyst estimates of $54.98 million. During the same period in the prior year, the business earned $0.37 EPS. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. On average, sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.85 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, August 29th. Shareholders of record on Thursday, August 15th were issued a $0.16 dividend. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $0.64 annualized dividend and a yield of 0.70%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 42.38%.

Insiders Place Their Bets

In related news, CEO George W. Lemaitre sold 27,030 shares of the stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $86.27, for a total value of $2,331,878.10. Following the completion of the transaction, the chief executive officer now directly owns 1,958,328 shares in the company, valued at approximately $168,944,956.56. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CEO George W. Lemaitre sold 27,030 shares of the stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $86.27, for a total value of $2,331,878.10. Following the completion of the transaction, the chief executive officer now directly owns 1,958,328 shares in the company, valued at approximately $168,944,956.56. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director David B. Roberts sold 3,063 shares of the stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total transaction of $251,380.41. Following the completion of the transaction, the director now owns 14,114 shares of the company’s stock, valued at $1,158,335.98. The disclosure for this sale can be found here. In the last ninety days, insiders sold 43,251 shares of company stock worth $3,714,994. 10.79% of the stock is currently owned by corporate insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.